Jena

JENA, Germany and SHANGHAI, December 5, 2011 - Nearly all areas of the Group now have a local presence with state-of-the-art infrastructure The Jenoptik Group has pooled all its activities on the Chinese market and combined them within a 100 percent owned subsidiary.

JENA, Germany, October 28, 2011 - Occlutech, a leading European developer of septum occluders such as PFO and ASD devices as well as other innovative, minimally invasive cardiac implants, today announced that it got a favorable ruling in patent litigation with St Jude-AGA Medical from the District Court of Milan in Italy.

JENA, Germany, September 26, 2011 - Occlutech, a leading European developer of implants for treating structural heart disease today announced that its CEO, Mr Tor Peters, has obtained a favorable ruling from the district court in Dsseldorf in patent litigation initiated personally against him by St Jude AGA Medical.

JENA, Germany, August 24, 2011 - Occlutech, a leading European developer of medical implants treating structural heart disease such as PFO, ASD and LAA today announced the closing of a 15 million Euro investment into Occlutech.

JENA, Germany, May 12, 2011 - Occlutech GmbH, a leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced that it has received a favourable court ruling from the German Supreme Court, (BGH), in Karlsruhe, Gerrmany in patent litigation initiated by AGA Medical Inc., now part of St.